[Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
In a considerable part of breast carcinomas the amount of cell surface Her2/neu receptors has been increased such that it becomes the main factor defining the behaviour of the tumor. At the same time, in such amount, this receptor is easily detectable by simple, routine pathological methods. If we are aware of the exact biological characteristics of a given tumor, targeted therapy may be used since an antibody against the Her2 receptor is already available. This drug, called trastuzumab (Herceptin), has been used in advanced breast carcinoma as adjuvant or primary treatment. In clinical trials its advantage in early stage breast carcinomas has been investigated so far.
Kulka
Janina
J
Orvostudományi Kar, II. Pathologiai Intézet, Budapest. kj@korb2.sote.hu
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000187:drug effects; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab